Abstract Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid) which significantly limits their applicability. In contrast, imaging based biomarkers can provide […]
Will posttranslational modifications of brain proteins provide novel serological markers for dementias?
January 1, 2012
Int J Alzheimers Dis